Australia markets open in 6 hours 8 minutes

ClearPoint Neuro, Inc. (CLPT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
6.68+0.29 (+4.54%)
At close: 04:00PM EST
6.80 +0.12 (+1.80%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.39
Open6.37
Bid6.05 x 1100
Ask6.65 x 800
Day's range6.37 - 6.77
52-week range4.05 - 10.95
Volume310,464
Avg. volume126,349
Market cap164.784M
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)-0.89
Earnings date12 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.67
  • GlobeNewswire

    ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

    SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company’s 2023 fourth quarter and full year results o

  • GlobeNewswire

    ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

    SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the pricing of its underwritten public offering of 2,307,694 shares of its common stock at a price to the public of $6.50 per share. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 346,154 shares of its common s

  • GlobeNewswire

    ClearPoint Neuro Launches Proposed Public Offering of Common Stock

    SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the commencement of a proposed underwritten public offering of its shares of common stock. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount